即时询价 ×
* 必填项
请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.
CAS号 | 2152628-33-4 | 货号 | BCP29047 |
中文名 | 塞尔帕替尼 | ||
英文名 | Selpercatinib | ||
中文别名 | 塞卡替尼; | ||
英文别名 | LOXO-292;LOXO 292;LOXO292; | ||
SMILES | CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O | ||
化学名称 | |||
分子式 | C29H31N7O3 | 分子量 | 525.25 |
纯度 | 98% | 配送 | 惯例下常温包邮 |
产品描述 | Selpercatinib is an orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. In addition, selpercatinib targets, binds to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3), and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers. |
相关产品推荐
查看更多 >Tags:Selpercatinib 供应商,Selpercatinib 购买,Selpercatinib 生产,Selpercatinib 批量,Selpercatinib 供应,Selpercatinib 订购,Selpercatinib 采购